CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
On April 15, 2019, the New CTS Laboratory Information System has been successfully implemented in Po...
On February 18, 2019, the new CTS Laboratory Information System was successfully implemented in Tamp...
We have now added a new section called the "Assay History List" to the "At A Gla...
Josh Moon has been appointed Chief Operating Officer (COO) at Creative Testing Solutions (CTS), effe...